Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
26 sept. 2024 08h00 HE
|
Genevant Sciences
SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies...
Global Bispecific Antibodies Clinical Trials Market Size FDA Approved Bispecific Antibodies Insight
26 sept. 2024 06h52 HE
|
KuicK Research
Delhi, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development...
CD47 Targeted Cancer Immunotherapy Drugs Clinical Trials FDA Approval Insight
26 sept. 2024 06h09 HE
|
KuicK Research
Delhi, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 Report Highlights Global & Regional Market Opportunity...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
23 sept. 2024 07h30 HE
|
BioAtla, Inc.
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and...
SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight
19 sept. 2024 07h34 HE
|
KuicK Research
Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership...
Comstock Fuels Executes International License Agreement
18 sept. 2024 11h10 HE
|
Comstock Inc.
VIRGINIA CITY, Nev., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced execution of a binding agreement between Comstock Fuels Corporation...
Bispecific Antibody Drug Conjugates Clinical Trials Insight
17 sept. 2024 07h14 HE
|
KuicK Research
Delhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The global market for bispecific antibody-drug conjugates (BsADCs) has experienced remarkable expansion, attributed to their revolutionary capabilities in...
Adeia and LG Electronics Renew Media IP License Agreement
16 sept. 2024 07h18 HE
|
Adeia Inc.
SAN JOSE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), a leading technology company bringing technology from incubation to reality, today announced the renewal of its...
PodcastOne (Nasdaq: PODC) Acquires Exclusive Multi-Year Sales and Distribution Rights to Fool Coverage with Manny MUA and Laura Lee Podcast
13 sept. 2024 08h00 HE
|
PodcastOne
Fool Coverage Has 153 Episodes Since Its Launch in 2021 17th New Podcast Joining PodcastOne Network This Fiscal Year, 45th in Last 12 Months 3.8 Billion All-Time Network Downloads LOS...
Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Commercial Launch Market Forecast 2029
12 sept. 2024 07h49 HE
|
KuicK Research
Delhi, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029 Report: Report Answers...